• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rituximab in the treatment of anti-HMGCR immune-mediated necrotizing myopathy: Two cases successfully treated.

作者信息

Micheli Giulia, Salvati Lorenzo, Palterer Boaz, Vivarelli Emanuele, Mazzoni Alessio, Volpi Nila, Vultaggio Alessandra, Matucci Andrea, Cosmi Lorenzo, Cammelli Daniele, Parronchi Paola

机构信息

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Flow Cytometry Diagnostic Center and Immunotherapy, Careggi University Hospital, Florence, Italy.

出版信息

Rheumatol Immunol Res. 2025 Jul 1;6(2):110-113. doi: 10.1515/rir-2025-0014. eCollection 2025 Jun.

DOI:10.1515/rir-2025-0014
PMID:40606853
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12212632/
Abstract
摘要

相似文献

1
Rituximab in the treatment of anti-HMGCR immune-mediated necrotizing myopathy: Two cases successfully treated.利妥昔单抗治疗抗3-羟基-3-甲基戊二酰辅酶A还原酶免疫介导的坏死性肌病：两例成功治疗病例
Rheumatol Immunol Res. 2025 Jul 1;6(2):110-113. doi: 10.1515/rir-2025-0014. eCollection 2025 Jun.
2
Clinical and persistent remission in anti-HMGCR immune-mediated necrotizing myopathy to a single cycle of rituximab - a case-based review.抗 HMGCR 免疫介导性坏死性肌病单次利妥昔单抗治疗达到临床和持续缓解：基于病例的综述。
ARP Rheumatol. 2024 Jul-Sep;3(3):231-236. doi: 10.63032/ZVNO7794.
3
Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report.利妥昔单抗用于难治性抗3-羟基-3-甲基戊二酰辅酶A还原酶免疫介导的坏死性肌病：一例报告。
Intractable Rare Dis Res. 2021 May;10(2):122-125. doi: 10.5582/irdr.2020.03144.
4
Initial seronegative immune-mediated necrotising myopathy with subsequent anti-HMGCR antibody development and response to rituximab: case report.初始血清学阴性的免疫介导坏死性肌病伴随后抗3-羟基-3-甲基戊二酰辅酶A还原酶（HMGCR）抗体产生及对利妥昔单抗的反应：病例报告
BMC Rheumatol. 2020 Jun 30;4:29. doi: 10.1186/s41927-020-00128-5. eCollection 2020.
5
Statins as a possible cause of inflammatory and necrotizing myopathies.他汀类药物可能导致炎症性和坏死性肌病。
Atherosclerosis. 2012 May;222(1):15-21. doi: 10.1016/j.atherosclerosis.2011.11.005. Epub 2011 Nov 16.
6
Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy.利妥昔单抗治疗难治性抗 HMGCR 免疫介导的坏死性肌病。
J Rheumatol. 2019 Jun;46(6):623-627. doi: 10.3899/jrheum.171495. Epub 2018 Dec 15.
7
Persistent exanthema mainly on the trunk with pathologically dermal interstitial mucin as anti-HMGCR myopathy-associated skin rash: Case series.持续性皮疹主要位于躯干，病理表现为真皮间质黏蛋白沉积，为抗3-羟基-3-甲基戊二酰辅酶A还原酶（HMGCR）肌病相关皮疹：病例系列报道
J Dermatol. 2025 Jun;52(6):1083-1089. doi: 10.1111/1346-8138.17717. Epub 2025 Mar 28.
8
Statin-associated anti-HMGCR immune-mediated necrotizing myopathy with dermatomyositis-like features: A case report.具有皮肌炎样特征的他汀类药物相关抗HMGCR免疫介导坏死性肌病：一例报告
SAGE Open Med Case Rep. 2020 Dec 29;8:2050313X20984120. doi: 10.1177/2050313X20984120. eCollection 2020.
9
Immune-Mediated Necrotizing Myopathy.免疫介导性坏死性肌病。
Curr Rheumatol Rep. 2018 Mar 26;20(4):21. doi: 10.1007/s11926-018-0732-6.
10
Pediatric Immune-Mediated Necrotizing Myopathy: A Single-Center Retrospective Cohort Study.儿童免疫介导性坏死性肌病：一项单中心回顾性队列研究
Pediatr Neurol. 2025 Jun;167:33-41. doi: 10.1016/j.pediatrneurol.2025.03.002. Epub 2025 Mar 14.

本文引用的文献

1
Clinical and persistent remission in anti-HMGCR immune-mediated necrotizing myopathy to a single cycle of rituximab - a case-based review.抗 HMGCR 免疫介导性坏死性肌病单次利妥昔单抗治疗达到临床和持续缓解：基于病例的综述。
ARP Rheumatol. 2024 Jul-Sep;3(3):231-236. doi: 10.63032/ZVNO7794.
2
Anti-HMGCR immune-mediated necrotising myopathy: Addressing the remaining issues.抗 HMGCR 免疫介导的坏死性肌病：解决尚存问题。
Autoimmun Rev. 2023 Dec;22(12):103468. doi: 10.1016/j.autrev.2023.103468. Epub 2023 Oct 24.
3
Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report.
利妥昔单抗用于难治性抗3-羟基-3-甲基戊二酰辅酶A还原酶免疫介导的坏死性肌病：一例报告。
Intractable Rare Dis Res. 2021 May;10(2):122-125. doi: 10.5582/irdr.2020.03144.
4
Statin-induced anti-HMGCR antibody-related immune-mediated necrotising myositis achieving complete remission with rituximab.他汀类药物诱导的抗HMGCR抗体相关免疫介导坏死性肌炎经利妥昔单抗治疗实现完全缓解
BMJ Case Rep. 2019 Dec 1;12(11):e232406. doi: 10.1136/bcr-2019-232406.
5
Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy.利妥昔单抗治疗难治性抗 HMGCR 免疫介导的坏死性肌病。
J Rheumatol. 2019 Jun;46(6):623-627. doi: 10.3899/jrheum.171495. Epub 2018 Dec 15.
6
Anti-HMGCR Myopathy.抗 HMGCR 肌病。
J Neuromuscul Dis. 2018;5(1):11-20. doi: 10.3233/JND-170282.
7
Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations.他汀类药物引起的肌肉疼痛和肌炎：发病机制和临床建议的更新。
Expert Rev Clin Immunol. 2018 Mar;14(3):215-224. doi: 10.1080/1744666X.2018.1440206. Epub 2018 Feb 23.
8
224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016.第224届ENMC国际研讨会：免疫介导性坏死性肌病的临床-血清学-病理学分类，荷兰赞德福特，2016年10月14日至16日。
Neuromuscul Disord. 2018 Jan;28(1):87-99. doi: 10.1016/j.nmd.2017.09.016. Epub 2017 Oct 23.
9
Anti-HMGCR antibody-associated necrotizing myopathy: diagnosis and treatment illustrated using a case report.抗3-羟基-3-甲基戊二酰辅酶A还原酶（HMGCR）抗体相关坏死性肌病：通过病例报告阐述诊断与治疗
Scand J Rheumatol. 2016 Oct;45(5):427-9. doi: 10.3109/03009742.2015.1132761. Epub 2016 Feb 17.
10
Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.在抗3-羟基-3-甲基戊二酰辅酶A还原酶相关的自身免疫性肌病中，抗体水平与肌酸激酶水平及肌力相关。
Arthritis Rheum. 2012 Dec;64(12):4087-93. doi: 10.1002/art.34673.